Privacy Practices

THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY.

I. Who We Are

This Notice of Privacy Practices (“Notice”) describes the privacy practices of RIVO, LLC and its affiliates, including certain affiliated professional entities, their physicians, health care practitioners, and other personnel (“we” or “us”).

II. Our Privacy Obligations

We are required by law to maintain the privacy of your health information (“Protected Health Information” or “PHI”) and to provide you with this Notice of our legal duties and privacy practices with respect to your PHI. We are also obligated to notify you following a Breach of unsecured PHI. When we use or disclose your PHI, we are required to abide by the terms of this Notice (or other notice in effect at the time of the use or disclosure).

III. Permissible Uses and Disclosures Without Your Written Authorization

In certain situations, which we describe in Section IV below, we must obtain your written authorization in order to use and/or disclose your PHI. We do not need any type of authorization, however, for the following uses and disclosures:

A. Uses and Disclosures For Treatment, Payment and Health Care Operations

We may use and disclose PHI, but not your “Highly Confidential Information” (defined in Section IV.B below), in order to treat you, obtain payment for services provided to you, and conduct our “Healthcare Operations” as detailed below:

Treatment. We may use and disclose your PHI to provide treatment, for example, to diagnose and treat your injury or illness. We may also disclose PHI to other health care providers involved in your treatment.

Payment. In most cases, we may use and disclose your PHI to obtain payment for services that we provide to you.

Healthcare Operations. We may use and disclose your PHI for our healthcare operations which include internal administration and planning and various activities that improve the quality and cost effectiveness of the care that we deliver to you.

B. Disclosure to Relatives, Close Friends and Other Caregivers

We may use or disclose your PHI to a family member, other relative, a close personal friend, or any other person identified by you when you are present for, or otherwise available prior to the disclosure, if we:

  1. obtain your agreement

  2. provide you with the opportunity to object to the disclosure and you do not object

  3. reasonably infer that you do not object to the disclosure

If you are not present, or the opportunity to agree or object cannot practicably be provided because of your incapacity or an emergency circumstance, we may exercise professional judgment to determine whether a disclosure is in your best interests.

C. Public Health Activities

We may disclose your PHI for public health activities such as reporting disease, injury, abuse, exposure risks, and workplace-related illnesses as permitted by law.

D. Victims of Abuse, Neglect or Domestic Violence

If we reasonably believe you are a victim of abuse, neglect, or domestic violence, we may disclose your PHI to a governmental authority authorized by law to receive such reports.

E. Health Oversight Activities

We may disclose your PHI to a health oversight agency responsible for monitoring the health care system and compliance with government health programs.

F. Judicial and Administrative Proceedings

We may disclose your PHI in the course of a judicial or administrative proceeding in response to a legal order or other lawful process.

G. Law Enforcement Officers

We may disclose your PHI to law enforcement officials as required or permitted by law.

H. Decedents

We may disclose your PHI to a coroner, medical examiner, or funeral director as authorized by law.

I. Research

We may use or disclose your PHI if an Institutional Review Board approves a waiver of authorization.

J. Health or Safety

We may disclose your PHI to prevent or lessen a serious and imminent threat to a person’s or the public’s health or safety.

K. Specialized Government Functions

We may disclose PHI for specialized government functions such as military or national security activities.

L. Workers’ Compensation

We may disclose PHI as necessary to comply with workers’ compensation laws.

M. As Required By Law

We may disclose PHI when required by law.

IV. Uses and Disclosures Requiring Your Written Authorization

We must obtain written authorization for marketing uses, sales of PHI, or other disclosures not described in this Notice.

You may revoke your authorization at any time by submitting a written request to hello@rivohealth.co

V. Your Rights Regarding Your Protected Health Information

You have the right to:

  • Request restrictions on PHI disclosures

  • Receive confidential communications

  • Inspect and copy your health information

  • Request amendments to your records

  • Receive an accounting of disclosures

Requests regarding your records or amendments can be submitted to:

hello@rivohealth.coe and Duration of This Notice

Effective Date: January 1, 2024

We may update this Notice at any time. Updated versions will be posted on our website.

VII. Privacy Officer

For questions about this Notice or your privacy rights, please contact:

RIVO, LLC
hello@rivohealth.co

RIVO guarantee

Free, expedited delivery

Doctor-led plans & coaching

No hidden fees

hello@rivohealth.co

1309 Coffeen Avenue STE 1200

Sheridan Wyoming 82801

*The assessment made available on the RIVO website does not create a doctor-patient relationship between the individual completing the assessment and RIVO.

OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to

determine if an individual does not qualify for GLP-1s. The answers an individual provides to the RIVO assessment consequently determine if the individual is screened

out of eligibility for GLP-1 medication, and an OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription.

OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and

consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from

compounded medications found on the RIVO platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations.

Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for

safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and

medical history.

We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of

compounded medication. RIVO does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the

website.

*The assessment made available on the RIVO website does not create a doctor-patient relationship between the individual completing the assessment and RIVO. OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the RIVO assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and an OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients. All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the RIVO platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history. We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. RIVO does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers

We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies

to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

Pharmacy Providers

We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a

reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone.

RIVO patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using

medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4

mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. RIVO patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the RIVO Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be

prescribed for weight loss. The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to

their respetive owners. Medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health, affiliated networks for medical professional corporations and

associations. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative

of RIVO patient experience.

Medication is included in the cost of the RIVO Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners. Medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health, affiliated networks for medical professional corporations and associations. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative of RIVO patient experience.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or

warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or AI portraying doctors and

are not licensed medical professionals.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals.

Testimonials on the website are from RIVO patients. For patient privacy, images representing those testimonials may use models or AI.